SCHEMBL25397902

SCHEMBL25397902

OCc1nnc(-c2ccc(F)c(F)c2)s1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
QPCTL Q9NXS2 5/20 0.47
SNCA P37840 1/20 0.41
QPCT Q16769 4/20 0.38
HDAC6 Q9UBN7 1/20 0.38
BLM P54132 1/20 0.37
HSD17B1 P14061 2/20 0.37
HSD17B2 P37059 1/20 0.37
CYP17A1 P05093 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NOTUM Q6P988 1/20 0.34
GUSB P08236 1/20 0.34
CDK2 P24941 1/20 0.33
AKT1 P31749 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31408961 1.00 QPCTL (0.47) QPCTLSNCAQPCTHDAC6BLM
SCHEMBL25396568 0.86 KDM4E (0.43) QPCTLSNCAQPCTHDAC6KDM4E
SCHEMBL31408954 0.86 KDM4E (0.43) QPCTLSNCAQPCTHDAC6KDM4E
SCHEMBL25399398 0.83 QPCTL (0.47) QPCTLSNCAQPCTHDAC6BLM
SCHEMBL25398740 0.83 KIF11 (0.54) CYP11B1CYP11B2
SCHEMBL31408960 0.83 KIF11 (0.54) CYP11B1CYP11B2
SCHEMBL25433860 0.83 HDAC6 (0.36) QPCTLSNCAQPCTHDAC6HSD17B1
SCHEMBL13899422 0.81 HDAC1 (0.43) BLMKDM4E
SCHEMBL30046069 0.79 KDM4E (0.59) QPCTLHSD17B1HSD17B2KDM4ENOTUM
SCHEMBL27163556 0.79 KDM4E (0.59) QPCTLHSD17B1HSD17B2KDM4ENOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197363-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME CUREVERSE INCORPORATED (KR) 2025-06-19 US disclosed
EP-4495106-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2025-01-22 EP disclosed
WO-2023177146-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME 재단법인 대구경북첨단의료산업진흥재단 2023-09-21 WO disclosed
WO-2023177146-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME 재단법인 대구경북첨단의료산업진흥재단 2023-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197363-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME PPARD, PPARG, PPARA QPCTL 2697/4885SNCA 3986/4885QPCT 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.